Novel Immunotherapy Combinations
Babar Bashir1,2, Melissa A Wilson3
1Departments of Medical Oncology, Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 700, Philadelphia, PA, 19107, USA.
Purpose Of Review:
The last decade witnessed an explosion in immunotherapeutic agent approvals for various malignancies. The success of immune checkpoint inhibitors (CTLA-4 and PD-1/PD-L1) in melanoma quickly sprung to other cancer types and are considered the emerging face of oncology.
Recent Findings:
Antibodies to CTLA-4 were first to enter the field, quickly followed by PD-1/PD-L1 inhibitors. Combination anti-CTLA4 and anti-PD-1/PD-L1 therapies were investigated, and after demonstrating improved responses, rapidly gained approval. Certain tumor types previously considered non-immunogenic also demonstrated durable responses which has been a remarkable discovery. However, not all tumor types respond to immunotherapies and it is widely recognized that tumor-specific immune inflammatory status predicts the best responders. Ongoing translational work indicates specific upregulation in additional immune checkpoints that circumvent response to anti-CTLA4 and anti-PD-1/PD-L1 antibodies. Here, we provide a comprehensive review of promising therapies on the horizon with unique combinations designed to overcome resistance or expand the pool of treatment responders.
Insights
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1/ligand 1), have transformed oncology. New combination therapies aim to improve responses and overcome resistance in various malignancies.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- The last decade has seen significant growth in immunotherapeutic agent approvals for diverse cancers.
- Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have shown remarkable success, expanding to numerous cancer types.
Purpose of the Study:
- To review promising novel immunotherapies and combination strategies.
- To address resistance mechanisms and expand treatment response pools.
Main Methods:
- Comprehensive literature review of recent advancements in cancer immunotherapy.
- Analysis of emerging immune checkpoints and combination therapies.
Main Results:
- Combination therapies (anti-CTLA4 and anti-PD-1/PD-L1) have demonstrated improved patient responses and gained regulatory approval.
- Tumor-specific immune inflammatory status is a key predictor of response to immunotherapy.
Conclusions:
- Despite successes, not all tumor types respond to current immunotherapies.
- Further research into novel immune checkpoints and combination strategies is crucial for overcoming resistance and broadening treatment applicability.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...